ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2604

Cross-Sectional Relationship Between Sarcopenic Obesity and Knee Osteoarthritis: The Johnston County Osteoarthritis Project
Abstract Number: 2605

Do Patients Recall Their Rheumatic Diagnoses Accurately? A Comparison by Disease Type
Abstract Number: 2606

The Impact of Social Media and Artificial Intelligence on Illness Perception and Treatment Adherence in Patients with Rheumatic Diseases
Abstract Number: 2607

ERS-RA as a Tool for Cardiovascular Risk Prediction in Established Rheumatoid Arthritis: An External Validation
Abstract Number: 2608

Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis
Abstract Number: 2609

Evaluation of the Performance of Candidate Enthesitis Ultrasound Scoring Systems for Psoriatic Arthritis Diagnosis – DUET Study
Abstract Number: 2610

Imaging remission in aortitis associated with giant cell arteritis. Multicenter study with tocilizumab in monotherapy and combined therapy
Abstract Number: 2611

Exploring the Role of a Lung Ultrasound Score in the Assessment of Severity of Connective Tissue Disease-Related Interstitial Lung Disease
Abstract Number: 2612

Automated, Artificial Intelligence-supported Sonographic Examination of the Hands for the Detection and Quantification of Arthritis and Osteoarthritis in the Hand and Finger Joints in Outpatient Rheumatology Care
Abstract Number: 2613

Ga-FAPI-04 PET/CT reveals increased fibroblast activation in synovial and enthesial tissues of psoriasis patients with arthralgia and predicts the development of psoriatic arthritis
Abstract Number: 2614

Impact of Vagus Nerve-Mediated Neuroimmune Modulation on structural joint damage using Gd-MRI RAMRIS imaging in Biologic-Experienced Patients with Rheumatoid Arthritis
Abstract Number: 2615

The Cost of Complexity: Financial Toxicity in Rheumatic Disease, Cancer, and Their Intersection
Abstract Number: 2616

Real-World Implication of Clinical Disease Activity Index (CDAI) Utilization on Treatment Decisions and Clinical Outcomes in Rheumatoid Arthritis
Abstract Number: 2617

Design and Initial Results from a Cluster Randomized Trial of a Provider-Facing Immunization Dashboard to Improve Shingrix Vaccination in the Veterans Health Administration
Abstract Number: 2618

Effect of Implementing a Dashboard with or without a Best Practice Alert on HLA-B*58:01 Testing Rates among Allopurinol Users at VA Medical Centers

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].